Piper Sandler downgraded Reneo Pharmaceuticals to Neutral from Overweight with a price target of $4, down from $25, after the company announced that its pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies, or PMM, did not meet its primary efficacy or secondary efficacy endpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RPHM:
- Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
- Block upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- Reneo Pharmaceuticals initiated with an Outperform at William Blair
- Reneo Pharmaceuticals files $300M mixed securities shelf
- Reneo Pharmaceuticals reports Q3 EPS (57c), consensus (57c)
